{
  "id": 129538,
  "title": "STAT+: The latest orphan drug exemptions may not be warranted, analysis finds",
  "url": "https://urgent.news/2026/08/04/stat-the-latest-orphan-drug-exemptions-may-not-be-warranted-analysis",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-08-04T12:05:01.000Z",
  "source": {
    "name": "STAT News",
    "slug": "stat-news",
    "url": "https://www.statnews.com/pharmalot/2026/08/04/latest-orphan-drug-exemptions-may-not-be-warranted-analysis-finds/"
  },
  "original_language": "en",
  "account": "The Inflation Reduction Act, enacted three years ago, permits Medicare to negotiate prices for specific drugs. Orphan drugs, designed to treat rare diseases, enjoy exemption from these negotiations if they have undergone only one FDA approval. However, the Orphan Cures Act, part of the One Big Beautiful Bill Act, expanded this exception to include drugs with multiple orphan indications. This amendment also postponed the schedule for potentially qualifying orphan drugs for price negotiation consideration. An analysis suggests that the latest orphan drug exemptions might not be justified.",
  "summary": "A new analysis questions the wisdom of a controversial provision in federal law that exempts so-called orphan drugs from Medicare pricing negotiations.",
  "key_points": [
    "Inflation Reduction Act permits Medicare to negotiate drug prices for orphan drugs.",
    "Orphan Cures Act expanded exemption to drugs with multiple orphan indications.",
    "Analysis suggests latest orphan drug exemptions may not be warranted."
  ],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}